重症卒中合并呼吸衰竭幸存者6个月时以患者和照护者为中心的结局:SETPOINT2试验子研究
SETPOINT2多中心试验在德国和美国比较严重卒中患者早期与延迟气管切开,本预设子研究评估6个月患者和照护者报告结局,不问气管切开时机。366例有6个月数据者中118例(32%)死亡,82例(22%)mRS 5,86例(23%)mRS 4,80例(22%)mRS 0-3;幸存者EQ-5D-5L指数中位0.3(IQR 0.1, 0.7),EQ-VAS中位40(IQR 20, 70);照护者45%为重度至极重度负担;70%照护者和97.8%幸存者对治疗结果满意,77%照护者和88.9%幸存者愿再次同意相同治疗。
要点
- 366例重症卒中合并呼吸衰竭并预计需气管切开(SETscore > 10)者6个月时32%死亡,22%达mRS 0-3,22%为mRS 5。
- 幸存者6个月健康状态明显下降:EQ-5D-5L指数中位0.3(IQR 0.1, 0.7),EQ-VAS中位40(IQR 20, 70)。
- 照护者负担平均BSFC-s 15.0 ± 6.9,45%为重度至极重度负担。
- 多数照护者(121/174,70%)和能应答幸存者(44/45,97.8%)对治疗结果满意;77%照护者和88.9%幸存者愿再次同意相同治疗。
- 较高EQ-5D-5L与女性、SAH诊断、在德国治疗(vs 美国)及无颅内压升高相关。
适用人群与场景
- 急性缺血性、出血性或蛛网膜下腔出血(SAH)卒中、呼吸衰竭且预计需气管切开(SETscore > 10)并接受神经重症治疗的患者;来自德国和美国的SETPOINT2多中心试验人群。
诊断标准与关键阈值
- 预计需气管切开以SETscore > 10界定;结局评估包括6个月电话访谈的mRS、EQ-5D-5L、EQ-VAS、BSFC-s短表及治疗结果满意度问题。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- SETPOINT2预设子研究,多中心(德国和美国),366例6个月有数据;急性缺血、出血或SAH卒中、呼吸衰竭、SETscore > 10;比较早期与延迟气管切开,本子研究评估6个月患者和照护者报告结局。
- 6个月时118/366(32%)死亡,82例(22%)mRS 5,86例(23%)mRS 4,80例(22%)mRS 0-3。
- 幸存者EQ-5D-5L指数中位0.3(IQR 0.1, 0.7),EQ-VAS中位40(IQR 20, 70)。
- 照护者BSFC-s平均15.0 ± 6.9,45%为重度至极重度负担。
- 121/174(70%)照护者和44/45(97.8%)幸存者对治疗结果满意;134/174(77%)照护者和40/45(88.9%)幸存者愿再次同意相同治疗。
- 较高EQ-5D-5L与女性、SAH诊断、在德国治疗(vs 美国)及无颅内压升高相关。
证据类型、等级与局限
- 多中心试验SETPOINT2的预设子研究;原文未给出证据等级或推荐强度;局限:仅366例有6个月数据,幸存者应答满意度问题者少(幸存者45例、照护者174例),为电话访谈评估。
对床旁实践的改变
- 对重症卒中合并呼吸衰竭并预计需气管切开者,急性期决策沟通可告知:6个月时约32%死亡、约22%达mRS 0-3,幸存者健康状态评分低且照护者负担重,但多数照护者和能应答幸存者对治疗满意并愿再次接受相同治疗;适用于SETscore > 10的缺血、出血或SAH卒中患者,不适用于未合并呼吸衰竭或SETscore ≤ 10者。
指南或共识出处
- SETPOINT2试验子研究(Neurocrit Care);原文未提及具体指南或共识名称。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: The multicenter trial SETPOINT2 comparing early versus delayed tracheostomy in severe stroke was conducted in Germany and the USA. A pre-specified aim was to assess 6-month patient- and caregiver-reported outcomes to better inform clinical decision-making in the acute phase of care, irrespective of tracheostomy timing.
METHODS: Patients had acute ischemic, hemorrhagic, or subarachnoid hemorrhage (SAH) strokes, respiratory failure, and a predicted necessity for tracheostomy (SETscore > 10). Outcome measures assessed by telephone interview 6 months after hospital admission included the modified Rankin scale (mRS), EuroQol 5D-5L (EQ-5D-5L), EuroQol Visual Analog Scale, Burden Scale for Family Caregivers short form (BSFC-s), and questions related to satisfaction with the treatment results.
RESULTS: Of 366 patients with available data at 6 months, 118 (32%) died, 82 (22%) achieved mRS 5 (severe disability), 86 (23%) mRS 4 (moderate disability), and 80 (22%) mRS 0-3 (partial to full independence). Survivors reported markedly reduced health status with median EQ-5D-5L Index of 0.3 (IQR 0.1, 0.7) and EQ-VAS of 40 (IQR 20, 70). Caregivers reported scores describing moderate burden, although 45% scored severe to very severe burden (mean ± SD 15.0 ± 6.9). Most caregivers (121/174, 70%) and survivors (44/45, 97.8%) were satisfied with the results of treatment, and 134/174 (77%) caregivers and 40/45 (88.9%) survivors would again consent to the treatment they received. Factors associated with higher EQ-5D-5L included female sex, SAH diagnosis, treatment in Germany (vs. the USA), and absence of elevated intracranial pressure.
CONCLUSIONS: For most patients 6 months after severe stroke with respiratory failure and neurocritical care treatment, physical disability and caregiver burden are profound. Nonetheless, most caregivers and nearly all survivors who were able to respond reported satisfaction with treatment and results of critical care including tracheostomy.
参考来源
- Jaffa MN, Seder DB, Muehlschlegel S, et al. Patient-and Caregiver-Centered Outcomes in Survivors of Severe Stroke with Respiratory Failure at 6 Months: A Substudy of the SETPOINT2 Trial. Neurocrit Care. 2026. PMID: 42477257. doi:10.1007/s12028-026-02591-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。